17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of
17-N-allylamino-17-demethoxygeldanamycin when given together with paclitaxel in treating
patients with metastatic or unresectable solid tumor. Drugs used in chemotherapy, such as
17-N-allylamino-17-demethoxygeldanamycin and paclitaxel, work in different ways to stop tumor
cells from dividing so they stop growing or die. Combining
17-N-allylamino-17-demethoxygeldanamycin with paclitaxel may kill more tumor cells